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Abstract
Background: 2015 was the target year for malaria goals set by the World Health Assembly and other international
institutions to reduce malaria incidence and mortality. A review of progress indicates that malaria programme
financing and coverage have been transformed since the beginning of the millennium, and have contributed to
substantial reductions in the burden of disease.
Findings: Investments in malaria programmes increased by more than 2.5 times between 2005 and 2014 from US$
960 million to US$ 2.5 billion, allowing an expansion in malaria prevention, diagnostic testing and treatment
programmes. In 2015 more than half of the population of sub-Saharan Africa slept under insecticide-treated
mosquito nets, compared to just 2 % in 2000. Increased availability of rapid diagnostic tests and antimalarial
medicines has allowed many more people to access timely and appropriate treatment. Malaria incidence rates have
decreased by 37 % globally and mortality rates by 60 % since 2000. It is estimated that 70 % of the reductions in
numbers of cases in sub-Saharan Africa can be attributed to malaria interventions.
Conclusions: Reductions in malaria incidence and mortality rates have been made in every WHO region and
almost every country. However, decreases in malaria case incidence and mortality rates were slowest in countries
that had the largest numbers of malaria cases and deaths in 2000; reductions in incidence need to be greatly
accelerated in these countries to achieve future malaria targets. Progress is made challenging because malaria is
concentrated in countries and areas with the least resourced health systems and the least ability to pay for system
improvements. Malaria interventions are nevertheless highly cost-effective and have not only led to significant
reductions in the incidence of the disease but are estimated to have saved about US$ 900 million in malaria case
management costs to public providers in sub-Saharan Africa between 2000 and 2014. Investments in malaria
programmes can not only reduce malaria morbidity and mortality, thereby contributing to the health targets of the
Sustainable Development Goals, but they can also transform the well-being and livelihood of some of the poorest
communities across the globe.
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Burden of disease, Poverty
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Background
2015 marked the end of the era of Millennium Develop-
ment Goals and the dawn of a new global agenda for
human health and prosperity, the Sustainable Develop-
ment Goals. It was also the target year for malaria goals
set by the World Health Assembly to reduce malaria
incidence and mortality and the launch of WHO’s
Global technical strategy for malaria 2016–2030. These
2015 goals and targets were supported by commitments
from endemic countries and the international commu-
nity to increase the financing of malaria programmes
and expand the coverage of malaria control interven-
tions namely, mosquito vector control through use of
insecticide-treated bednets and indoor residual spraying;
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malaria chemoprevention for pregnant women and for
children in areas with highly seasonal malaria; and
malaria diagnostic testing and treatment for malaria
cases. To assess progress in malaria control and elimin-
ation worldwide, the World Health Organization reviews
available information from malaria endemic countries
and implementing partners and publishes them in the
World malaria report [1]. The report shows that there
have been substantial gains in malaria programme finan-
cing and coverage since the beginning of the millennium
and that these have had a substantial impact on the
incidence of malaria. Nevertheless, significant challenges
lie ahead, particularly for the poorest countries in the
world and for substantial proportions of the populations
living in them.
Progress in malaria control and elimination
2000-2015
Financing of malaria control programmes
Malaria is concentrated in the poorest countries of the
world (see Fig. 1), and inadequate financing of malaria
programmes has long thwarted efforts to combat the
disease. Malaria programme financing rose from an
estimated US$ 960 million globally in 2005 to US$ 2.5
billion in 2014, which represents an unprecedented
increase but still falls short of the estimated US$ 5.1
billion needed annually to attain international targets for
malaria control and elimination (Fig. 2). Much of the
increase was driven by international funding which
accounted for 78 % of malaria programme funding in
2014, with most directed to the WHO African Region
(82 %). Domestic contributions are underestimated because
national malaria control programme (NMCP) expenditures
reported to WHO are generally restricted to direct expendi-
tures on malaria control activities by NMCPs, and exclude
health system costs associated with treating patients. The
increased funding for malaria was accompanied by a
40-fold increase in spending on malaria commodities
(insecticide-treated mosquito nets (ITNs), insecticides
and spraying equipment for indoor residual spraying
(IRS), rapid diagnostic tests (RDTs) and artemisinin
combination therapies (ACTs), from US$ 40 million
in 2004 to US$ 1.6 billion in 2014. Malaria commod-
ities accounted for 82 % of international malaria
spending in 2014 with ITNs responsible for 63 % of
total commodity spending, followed by ACT (25 %),
RDTs (9 %) and IRS (3 %).
Vector control
Increased expenditure on malaria commodities moti-
vated a massive increase in the number of ITNs deliv-
ered by manufacturers to malaria-endemic countries,
from 6 million in 2004 to 189 million in 2014 and 178
million in 2015 with more than a billion ITNs delivered
over this period. The estimated proportion of the popu-
lation at risk in sub-Saharan Africa with access to an
ITN in their household has consequently increased from
7 % in 2005 to 67 % in 2015 (95 % CI: 61–71 %) while
the proportion of the population at risk sleeping under
an ITN rose from 46 % in 2014 (95 % CI: 42–50 %) to
55 % in 2015 (95 % CI: 50–58 %) (Fig. 3). A comparison
of the proportion of the population with access to an
ITN with the proportion sleeping under an ITN indi-
cates that a high proportion of those with access to an
ITN sleep under it (about 82 %). Worldwide, 116 million
people were protected by IRS in 2014, a decline since
Fig. 1 Gross national income per capita versus estimated number of malaria cases, by WHO region, 2015. AFR, African Region; AMR, Region of
the Americas; EMR, Eastern Mediterranean Region; SEAR, South-East Asia Region; WPR, Western Pacific Region. Source: WHO estimates and the
World Bank Data Bank
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2010 when proportion of the population at risk that was
protected was 5.7 % compared to 3.4 % in 2014. Com-
bining data on the proportion of the population with ac-
cess to an ITN in a household and the proportion of
people protected by IRS in sub-Saharan Africa, the esti-
mated proportion of the population for whom vector
control had been made available increased from 1 % in
2000 to 59 % in 2014. This still falls short of the univer-
sal access target (100 %) in the 2011 update to the
Global Malaria Action Plan (GMAP).
Chemoprevention
The proportion of pregnant women receiving at least
three doses of intermittent preventive treatment in preg-
nancy (IPTp) increased between 2009 and 2014. In 2014,
52 % of eligible pregnant women received at least one
dose of IPTp, 40 % received two or more doses, and
17 % received three or more doses. The difference
between the proportion of women attending antenatal
care clinics and the proportions receiving the first and
subsequent doses of IPTp suggests that opportunities to
deliver IPTp at these clinics were missed. Adoption and
implementation of chemoprevention in children has
been more limited. As of 2014, six of the 15 countries
for which WHO recommends seasonal malaria chemo-
prevention (SMC) had adopted the policy. Only one
country, Chad, reported adoption of an intermittent
preventive treatment for infants (IPTi) policy in 2014.
Diagnostic testing and treatment
The estimated proportion of suspected malaria cases
presenting for care in the public sector that receive a
Fig. 2 Investments in malaria control activities by funding source, 2005–2014. AMFm, Affordable Medicine Facility-malaria; Global Fund, Global
Fund to Fight AIDS, Tuberculosis and Malaria; NMCP, national malaria control programme; UK, United Kingdom; USA, United States of America
Annual values have been converted to constant 2014 US$ using the gross domestic product (GDP) implicit price deflator from the USA in order
to measure funding trends in real terms. Source: ForeignAssistance.gov, Global Fund, NMCPs, Organisation for Economic Co-operation and
Development (OECD) creditor reporting system (CRS), the World Bank Data Bank
Fig. 3 Proportion of population at risk with access to an ITN and proportion sleeping under an ITN, sub-Saharan Africa, 2000–2015. ITN,
insecticide-treated mosquito net. Source: Insecticide-treated mosquito net coverage model from Malaria Atlas Project (3), with further
analysis by WHO
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malaria diagnostic test increased globally since 2005 and
quite dramatically in several WHO regions. The WHO
African Region had the largest increase in levels of
malaria diagnostic testing, from 36 % of suspected
malaria cases in 2005, to 41 % in 2010 and 65 % in
2014, primarily due to an increased use of rapid diag-
nostic tests (RDTs). The level of malaria diagnostic
testing is lower among febrile children seeking care
in the private sector than among those seeking care
in the public sector (Fig. 4). Among 18 nationally-
representative surveys conducted in sub-Saharan Africa
from 2013 to 2015, the median proportion of febrile
children who received a finger or heel stick in public
sector health facilities was 53 % (interquartile range
[IQR]: 35–57 %), whereas it was 36 % in the formal
private sector (IQR: 20–54 %) and 6 % in the informal
private sector (IQR: 3–9 %).
The estimated proportion of children in sub-Saharan
Africa aged under 5 years with P. falciparum malaria
and who were treated with an ACT is estimated to have
increased from less than 1 % in 2005 to 16 % in 2015
(range 12–22 %). While the proportion of children
treated with an ACT is increasing, the proportion
treated with other antimalarial medicines has decreased
over the same period. Nationally-representative house-
hold surveys conducted between 2004 and 2015 show an
increasing proportion of children with malaria who
receive any antimalarial treatment are given an ACT
(median 46 %, IQR 29–77 %, across surveys from 2013–
2015). Other children receive chloroquine (median 2 %,
IQR 0–10 %), sulfadoxine-pyrimethamine (SP) (median
5 %,IQR 1–18 %), and quinine (median 6 %, IQR 3–
9 %). The proportion of ACT antimalarial treatments
was lowest when care was sought from informal health-
care providers, such as market stalls or itinerant vendors
(Fig. 5).
Trends in malaria case incidence and mortality rates
The number of malaria cases is estimated to have fallen
from 262 million globally in 2000 (range 205–316
million) to 214 million in 2015 (range 149–303 million),
a decline of 18 %. Most cases in 2015 are estimated to
have occurred in the WHO African Region (88 %),
followed by the WHO South-East Asia Region (10 %)
and the WHO Eastern Mediterranean Region (2 %). The
incidence of malaria, which takes into account popula-
tion growth, is estimated to have decreased by 37 %
between 2000 and 2015. It is estimated that 57 of 106
countries that had ongoing transmission in 2000 reduced
malaria incidence by >75 % (Fig. 6). A further 18 coun-
tries are estimated to have reduced malaria incidence by
50–75 %. Thus, the target of Millennium Development
Goal (MDG) 6 “to have halted and begun to reverse the
incidence of malaria” (Target 6C) has been achieved.
The number of malaria deaths fell from an estimated
839 000 globally in 2000 (range 653 000 to 1.1 million),
to 438 000 in 2015 (range 236 000–635 000), a decline
of 48 %. Most deaths in 2015 remain in the WHO
African Region (90 %), followed by the WHO South-
East Asia Region (7 %) and the WHO Eastern Mediter-
ranean Region (2 %). The malaria mortality rate, which
takes into account population growth, is estimated
to have decreased by 60 % globally between 2000
and 2015. Thus, substantial progress has been made
towards the World Health Assembly target of redu-
cing the malaria burden by 75 % by 2015, and the
Roll Back Malaria (RBM) Partnership target of reducing
deaths to near zero.
Malaria in children
The proportion of children infected with malaria parasites
is estimated to have halved in endemic areas of Africa
since 2000. Infection prevalence among children aged
Fig. 4 Proportion of febrile children receiving a blood test, by health sector, sub-Saharan Africa, 2013–2015. Source: Nationally-representative
household survey data from demographic and health surveys and malaria indicator surveys
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2–10 years declined from 33 % in 2000 (uncertainty
interval: 31–35 %) to 16 % in 2015 (uncertainty interval:
14–19 %), with three quarters of this change occurring
after 2005.
Malaria remains a major killer of children, particu-
larly in sub-Saharan Africa, taking the life of a child
every 2 min. Nonetheless, the number of malaria
deaths in children aged under 5 years is estimated to
have decreased from 723 000 globally in 2000 (range
563 000–948 000) to 306 000 in 2015 (range 219
000–421 000). The bulk of this decrease occurred in
the WHO African Region, where the estimated num-
ber of deaths fell from 694 000 in 2000 (range 569
000–901 000) to 292 000 in 2015 (range 212 000–
384 000). As a result, malaria is no longer the lead-
ing cause of death among children in sub-Saharan
Africa as it was in 2000. In 2015, malaria was the
fourth highest cause of death, accounting for 10 %
of child deaths in sub-Saharan Africa (Fig. 7). Reduc-
tions in malaria deaths have contributed substantially
to progress towards achieving the MDG 4 target of
reducing the under-5 mortality rate by two thirds
between 1990 and 2015.
Cases and deaths averted
It is estimated that a cumulative 1.2 billion fewer
malaria cases and 6.2 million fewer malaria deaths
occurred globally between 2001 and 2015 than
would have been the case had incidence and mor-
tality rates remained unchanged since 2000. In sub-
Saharan Africa it is estimated that malaria control
interventions accounted for 70 % of the 943 million
fewer malaria cases occurring between 2001 and
2015, averting 663 million malaria cases (uncertainty
interval: 542–753 million) [2]. Of the 663 million
cases averted due to malaria control interventions, it
is estimated that 69 % of cases averted were due to
ITNs (uncertainty interval: 63–73 %), 21 % to ACT
(uncertainty interval: 17–29 %) and 10 % due to IRS
(uncertainty interval: 6–14 %) (Fig. 8).
Fig. 5 Proportion of febrile children receiving antimalarial treatments, by type, sub-Saharan Africa, 2013–2015. ACT, artemisinin-based combination
therapy; AQ, amodiaquine; CQ, chloroquine; Mono, monotherapy; SP, sulfadoxine-pyrimethamine; QN, quinine. Only shows results for a subset of
countries which have had household surveys in the stated years Source: Nationally-representative household survey data from demographic and
health surveys and malaria indicator surveys
Fig. 6 Estimated change in malaria case incidence 2000–2015, by WHO region. AFR, African Region; AMR, Region of the Americas; EMR, Eastern
Mediterranean Region; EUR, European Region; SEAR, South-East Asia Region; WPR, Western Pacific Region. Source: WHO estimates
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Progress to elimination
An increasing number of countries are moving towards
elimination of malaria. Whereas only 13 countries were
estimated to have fewer than 1000 malaria cases in 2000,
33 countries are estimated to have achieved this
milestone in 2015 (Fig. 9). Also, in 2014, there were 16
countries that reported zero indigenous cases (Argentina,
Armenia, Azerbaijan, Costa Rica, Iraq, Georgia, Kyrgyzstan,
Morocco, Oman, Paraguay, Sri Lanka, Tajikistan, Turkey,
Turkmenistan, United Arab Emirates and Uzbekistan). The
WHO European Region reported zero indigenous cases for
the first time in 2015, in line with the goal of the Tashkent
Declaration to eliminate malaria from the region by 2015.
Challenges remaining
Malaria programme financing and coverage have been
transformed since the beginning of the millennium, and
have contributed to reductions in the burden of disease.
However, progress has not been even. Decreases in case
incidence and mortality rates were slowest in countries
that had the largest numbers of malaria cases and deaths
in 2000; reductions in case incidence was 32 % in the 15
countries accounting for 80 % of cases in 2000, while
53 % in the rest. Reductions in incidence need to be
greatly accelerated in these countries if global progress is
to improve.
Millions of people still do not receive the malaria
prevention and treatment services they need. In sub-
Saharan Africa in 2014, an estimated 269 million of the
843 million people at risk of malaria lived in households
without any ITNs or IRS; 15 million of the 28 million
pregnant women at risk did not receive a dose of IPTp;
and between 68 and 80 million of the 92 million children
with malaria did not receive ACT. Malaria-endemic coun-
tries face considerable challenges to fill these gaps as the
disease is concentrated in countries and areas with the
least resourced health systems as exemplified by lower
staff: population ratios and greater use of informal private
sector providers. The ability of malaria-endemic countries
to strengthen health systems is constrained by low gross
Fig. 7 Leading causes of death among children aged under 5 years in sub-Saharan Africa, 2000–2015. Conditions that are responsible for more
than 10 deaths per 1000 live births during any time between 2000 and 2015 are shown. Source: WHO estimates
Fig. 8 Predicted cumulative number of malaria cases averted by interventions, sub-Saharan Africa, 2000–2015. ACT, artemisinin-based combination
therapy; IRS, indoor residual spraying; ITN, insecticide-treated mosquito net. Source: Malaria Atlas Project [3] estimates of cases averted attributable
to ITNs, ACTs, and IRS and WHO estimates of total cases averted
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national incomes and total domestic government
spending per capita. International spending on malaria
control is more evenly distributed in relation to
malaria burden, but, as indicated previously, a large
proportion of this funding is spent on commodities
and does not address fundamental weaknesses in
health systems. Thus, innovative ways of providing
services may be required to rapidly expand access to
malaria interventions such as community-based ap-
proaches and engaging with private sector providers.
While the lack of strong and adequately financed
delivery systems pose a continued challenge to mal-
aria control and elimination, significant biological
challenges also need to be faced including the lack
of tools to effectively diagnose and treat malaria due
to P. vivax and the emergence of parasite resistance
to antimalarial medicines and of mosquito resistance
to insecticides.
Looking to the future
To address the remaining and emerging challenges,
WHO developed the Global technical strategy for
malaria 2016–2030 (GTS 2016–2030) [2], adopted by
the World Health Assembly in May 2015. The strategy
sets the most ambitious targets for reductions in malaria
cases and deaths since the malaria eradication era
60 years ago, notably reductions in malaria incidence
and mortality rates of 90 % or greater by 2030, and the
elimination of malaria from at least 35 countries. Annual
investments in malaria control and elimination will need
to increase to US$ 8.7 billion by 2030 in order to achieve
these targets. The amount may seem prohibitive given
that current levels of investment are less than a third of
this total. However, malaria funding increased by more
than 2.5 times between 2005 and 2014 and similar rates
of increase over a fifteen year period would allow the
GTS 2016–2030 funding target to be achieved.
Conclusions
Global progress in reducing malaria is nothing short of
remarkable. Malaria case incidence has decreased by
37 % globally between 2000 and 2015 and malaria mor-
tality rates by 60 %. Investments in malaria interventions
have played a large part in bringing about these reduc-
tions, accounting for approximately 70 % of the decline
observed in sub-Saharan Africa between 2000 and
2015. Further reductions in malaria are possible and
are called for in the Global technical strategy for
malaria 2016–2030. However, annual investments in
malaria control and elimination will need to increase to
US$ 8.7 billion by 2030 in order to achieve the targets
set out in the GTS 2016–2030. While this total greatly
exceeds current investments, malaria interventions are
highly cost-effective and exhibit one of the highest
returns on investment in public health. Investments in
malaria programmes will not only strengthen health
systems and deepen the reductions in malaria morbidity
and mortality, thereby contributing to the health targets
of the SDGs, but they can also transform the well-being
and livelihood of some of the poorest communities
across the globe.
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